Fusion Antibodies plc

Equities

FAB

GB00BDQZGK16

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 09:05:12 31/05/2024 pm IST			5-day change	1st Jan Change
3.75 ^GBX	-1.32%		-1.32%	-11.76%

23/05	Celadon ships to US; Oxford BioDynamics-Goodbody pact	AN
23/05	Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic	CI

Fusion Antibodies plc Announces Directorate Change

February 16, 2021 at 12:30 pm IST

Fusion Antibodies plc announced that Paul Kerr stands down from the Board with immediate effect in order to pursue other opportunities. Richard Jones joins Paul will become a consultant to the company so that he can continue to support the company going forward.

Latest news about Fusion Antibodies plc

Celadon ships to US; Oxford BioDynamics-Goodbody pact	24/05	AN
Fusion Antibodies plc Announces New Contract with Existing Client Project to Develop Therapeutic	23/05	CI
EARNINGS AND TRADING: Software Circle & Beximco report higher revenue	01/05	AN
Fusion Antibodies inks commercial contract for OptiPhage library	15/04	AN
Fusion Antibodies Secures Contract to Set Up OptiPhage Library	15/04	MT
Fusion Antibodies plc Enters into Commercial Contract to Develop a Bespoke OptiPhageTM Library	15/04	CI
Sondrel wins USD23 million contract	27/02	AN
Fusion Antibodies Lands Antibodies Contract with Diagnostics Company	27/02	MT
Fusion Antibodies plc Receives First Purchase Order Under the Master Services Agreement	27/02	CI
Fusion Antibodies raises GBP1.4 million via placing	14/02	AN
Fusion Antibodies Raises GBP1 Million via Share Issue	14/02	MT
Fusion Antibodies strikes follow-on research and development project	06/02	AN
Fusion Antibodies Receives Follow-On Project from US Biotechnology Client	06/02	MT
AIM WINNERS & LOSERS: Beeks Financial Cloud is ahead of expectations	06/02	AN
Fusion Antibodies plc Receives Follow-On Project Award and R&D Update	06/02	CI
Fusion Antibodies gets tax credit from UK HMRC for OptiMAL platform	01/02	AN
Fusion Antibodies Receives R&D Tax Credit from UK Government	01/02	MT
FTSE 100 slips as miners hold down index	04/12	AN
Fusion Antibodies shares fall with revenue despite "positive" outlook	04/12	AN
AIM WINNERS & LOSERS: Cornerstone FS to beat 2023 expectations	04/12	AN
Fusion Antibodies plc Reports Earnings Results for the Half Year Ended September 30, 2023	04/12	CI
Fusion Antibodies plc Provides Revenue Guidance for the Fiscal Year 2024	04/12	CI
Fusion Antibodies Shares Rise on US Cancer Institute Collaboration	28/11	DJ
Fusion Antibodies shares up on deal with US National Cancer Institute	28/11	AN
AIM WINNERS & LOSERS: Totally swings to half-year loss on NHS blow	28/11	AN

Chart Fusion Antibodies plc

Duration

Period

More charts

Company Profile

Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The principal activity of the Company is the research, development, and manufacture of recombinant proteins and antibodies, particularly in the areas of cancer and infectious diseases. It is engaged in providing an integrated end-to-end range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications. It offers a range of services in antibody generation, development, characterization, optimization, and small-scale production. These services include antigen expression, purification and sequencing, antibody humanization using its proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for use downstream by the customer to produce material for clinical trials. It is also developing OptiMAL, a mammalian antibody library and discovery platform yielding fully human antibodies.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
FUSION ANTIBODIES PLC	-11.76%	45.5L
MODERNA, INC.	+43.36%	5.46TCr
IQVIA HOLDINGS INC.	-5.31%	3.99TCr
LONZA GROUP AG	+37.52%	3.88TCr
ICON PUBLIC LIMITED COMPANY	+14.75%	2.69TCr
CELLTRION, INC.	-12.56%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	1.88TCr
UNITED THERAPEUTICS CORPORATION	+25.12%	1.22TCr
BIO-TECHNE CORPORATION	+0.04%	1.22TCr
MEDPACE HOLDINGS, INC.	+26.04%	1.19TCr

Other Biotechnology & Medical Research